-
A phase I single-agent open-label dose-escalation study of oral ONC201 in patients with advanced solid tumors
Protocol: 051403
Principal Investigator: Mark Stein
Applicable Disease Sites: Kidney
Prostate
Any Site
Breast - Male
Brain and Nervous System
Melanoma, skin
-
UPCC 02614: The BAMM Trial: BRAF, Autophagy and MEK inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients with Advanced BRAF Mutant Melanoma.
Protocol: 091503
Principal Investigator: Janice Mehnert
Applicable Disease Sites: Melanoma, skin
-
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination with PD-1 Blocking Antibodies
Protocol: 051707
Principal Investigator: Ann Silk
Applicable Disease Sites: Hodgkin's Lymphoma
Lip, Oral Cavity and Pharynx
Any Site
Other Urinary
Bladder
Lung
Melanoma, skin
-
The Development and Evaluation of a Behavioral Intervention to Reduce Indoor Tanning
Protocol: 131315
Principal Investigator: Jerod Stapleton
Applicable Disease Sites: Melanoma, skin
-
Sun Protection and Skin Self-Examination Among Families Coping With Early Onset Melanoma: A Pilot Study
Protocol: 131516
Principal Investigator: Sharon Manne
Applicable Disease Sites: Melanoma, skin
-
NCI/CTEP# 9466: Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma and other solid tumors
Protocol: 091306
Principal Investigator: Janice Mehnert
Applicable Disease Sites: Melanoma, skin
Any Site
